Form 4: Entrada Therapeutics Insider Sells Shares

Entrada Therapeutics' Chief Financial Officer, Kory James Wentworth, sold 2,500 shares of common stock on April 1, 2026, as part of a pre-arranged trading plan.

Summary

• Kory James Wentworth, Chief Financial Officer of Entrada Therapeutics, Inc., reported a transaction on April 1, 2026.
• The transaction involved the sale of 2,500 shares of common stock.
• The sale was executed at a price of $12.95 per share.
• Following this transaction, Mr. Wentworth beneficially owns 119,010 shares of common stock.
• This sale was made under a Rule 10b5-1 trading plan adopted on March 6, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While insider selling can be a negative indicator, the transaction was executed under a pre-arranged Rule 10b5-1 plan, mitigating concerns about opportunistic selling based on non-public information.

Negatives

• Insider selling can sometimes be interpreted as a negative signal by the market, suggesting a lack of confidence in future stock performance, although this sale was conducted under a pre-established trading plan.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. It is a report of a past transaction.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan is a common strategy for executives to diversify their holdings or manage personal finances without triggering insider trading concerns, as these plans are established when the insider does not possess material non-public information.

Stakeholder Impact

• Shareholders: May view insider selling with caution, though the Rule 10b5-1 plan provides a degree of reassurance that the sale was not based on material non-public information.

Key Dates

Keywords

Form 4, Insider Trading, Entrada Therapeutics, Kory James Wentworth, Rule 10b5-1, Stock Sale, Beneficial Ownership